在抗凝治疗领域，一种新型单抗疗法正在展现其潜力。近期，Anthos Therapeutics公司宣布了其研发的凝血因子XI靶向单克隆抗体abelacimab在临床Ⅱ期试验AZALEA-TIMI71中的积极结果，这一成果被发表在《新英格兰医学杂志》上。研究发现，abelacimab在房颤患者中，较传统的直接口服抗凝药（DOAC）显著降低了出血事件的发生。该药物通过每月一次的150mg皮下注射，能够将 ...

Clinically significant reductions in bleeding underscore abelacimab’s strong potential to address an unmet need for patients ...

▎药明康德内容团队编辑日前，AnthosTherapeutics宣布，其在研凝血因子XI靶向单抗abelacimab在临床2期试验AZALEA-TIMI ...

在最新的《新英格兰医学杂志》上，药明康德报道了Anthos Therapeutics的重大进展：新型凝血因子XI靶向单抗abelacimab在2期临床试验AZALEA-TIMI71中展现出卓越的治疗效果。这项研究专注于房颤患者，表明与传统的直接口服抗凝药（DOAC）相比，abelacimab显著降低了出血事件的发生率，让此疗法的前景更为广阔。

Researchers have found in a new research that among patients with atrial fibrillation who are at moderate-to-high risk for ...

Discover how abelacimab reduces bleeding risks in AFib patients by effectively lowering free factor XI levels.

2025-01-24 08:14发布于江苏药明康德官方账号 日前，AnthosTherapeutics宣布，其在研凝血因子XI靶向单抗abelacimab在临床2期试验AZALEA-TIMI 71中获得的积极结果 ...

日前，AnthosTherapeutics宣布，其在研凝血因子XI靶向单抗abelacimab在临床2期试验AZALEA-TIMI 71中获得的积极结果发表在《新英格兰医学杂志》当中。

Abelacimab, a factor XI inhibitor, demonstrated a 62–69% reduction in major bleeding compared to rivaroxaban in atrial fibrillation patients at moderate-to-high stroke risk, with comparable safety and ...

Subcutaneous injection of abelacimab results in lower levels of free factor XI and significantly fewer bleeding events than ...